Study | Age (y) | FIGO stage | Size (cm) | Associated component | Metastatic site | Ascitic fluid cytology | Treatment | Outcome |
---|---|---|---|---|---|---|---|---|
Collins et al., 1991 [4] | 34 | IC | 16 | Mucinous cystadenoma & mucinous adenoCa | None | N/A (bloody 4 l) | TAH/BSO/OM + CDDP/CPA | DOD 8 months |
Khurana et al., 1994 [5] | 22 | I | 21 | Mucinous cystadenoma & mucinous adenoCa | None | N/A | RSO/AP + CBDCA + CPA | DOD 3 months |
Jones et al., 1996 [6] | 65 | IA | 16.5 | Mucinous cystadenoma | None | Negative (1.6 l) | TAH/BSO/OM/PLN/AP | DOD 10 months |
Eichhorn et al., 1996 [7] | 77 | IA | 15 | Endometrioid adenoCa grade 1 | None | N/A | TAH/BSO/LN & peritoneal biopsies | DOD 19 months |
36 | IA | 10 | Mucinous adenoCa | None | N/A | RSO/AP | Recent | |
45 | IB | 18 | Mucinous borderline tumor with small foci of mucinous adenoCa | None | N/A | TAH/BSO/OM + Chem | DOD 36 months | |
68 | IIB | 9 | Mucinous adenoCa | Right tube | N/A | TAH/RSO/OM/peritoneal biopsy | Lost to follow-up | |
Chen, 2000 [8] | 44 | IA | 25 | Mucinous intraepithelial adenoCa | None | N/A | TAH/BSO/OM + PTX + CBDCA | DOD 4 months |
Behnam et al., 2004 [9] | 27 | IA | 17 | Pure LCNEC | None | N/A | LSO/right OV & pelvic wall biopsies/PAN//OM/AP + PTX + CBDCA | NED 10 months |
Hirasawa, 2004 [10] | 56 | IIC | 18 | Mucinous adenoCa & dermoid cyst | Rectum | Positive (adenoCa) | TAH/BSO/rectal serosa resection/PLN | DOD 10 months |
35 | IC | N/A | Mucinous adenoma | None | N/A | TAH/BSO/OM + CDDP (ip) + high-dose Chem | NED 10 years | |
Ohira et al., 2004 [11] | 33 | IC | 11 | Endometrioid adenoCa grade 1 | None | Ruptured | LSO/right OV biopsy/OM + CPT-11/Nedaplatin | DOD 6 months |
Ahmed et al., 2005 [12] | 31 | N/A | 15 | Mucinous cystadenoma | N/A | N/A | N/A | N/A |
Lindboe, 2007 [13] | 64 | IA | 14 | Pure LCNEC | None | Negative | TAH/BSO/OM + Bleomycin/CDDP/Etoposide | NED 9 months |
Veras et al., 2007 [14] | 55 | I | 26 | Mucinous low malignant potential with intraepithelial Ca | N/A | N/A | TAH/BSO + platinum-based Chem | NED 68 months |
54 | I | 14 | Mucinous & endometrioid Ca | N/A | N/A | TAH/BSO + platinum-based Chem | NED 66 months | |
59 | I | 14 | High-grade adenoCa, not otherwise specified | N/A | N/A | BSO + platinum-based Chem | NED 28 months | |
22 | I | 21 | Mucinous low malignant potential with mucinous Ca | N/A | N/A | RSO/AP + platinum-based Chem | DOD 3 months | |
Tartaglia et al., 2008 [15] | 56 | IIA | 8 | Pure LCNEC | Endometrium | Negative | TAH/BSO/pelvic wall biopsies/OM/AP/PAN + PTX/CBDCA | NED 10 months |
Aslam et al., 2009 [16] | 76 | IIB | 30 | Pure LCNEC | Douglas pouch | N/A | TAH/BSO/OM/AP/PLN/PAN/Douglas pouch resection | DOD post operation |
Chenevert et al., 2009 [17] | 53 | I | 21 | Mucinous adenoCa & dermoid cyst | None | N/A | TAH/BSO/OM/PLN + CDDP/etoposide | DOD 7 months |
Oshita et al., 2011 [18] | 80 | IIC | 7 | Endometrioid adenoCa | Left tube, parametrium | Ruptured | TAH/BSO/PLN/OM /AP + PTX + CBDCA | NED 40 months |
65 | IC | 11 | Endometrioid adenoCa with squamous differentiation | None | Ruptured | TAH/BSO/OM + PTX/CBDCA | DOD 2 months | |
Lee et al., 2012 [19] | 40 | IA | 30 | Mucinous Ca | None | N/A | TAH/BSO/RPLN/OM/AP + PTX/CBDCA | NED 8 months |
Ki et al., 2014 [20] | 58 | IA | N/A | Pure LCNEC | None | N/A | TAH/BSO/OM/PLN + PTX/CDDP | DOD 17 months |
67 | IIB | 13 | Pure LCNEC | Pelvic peritoneum | N/A | TAH/BSO/RPLN/OM + PTX/CBDCA | NED 5 months | |
Asada et al., 2014 [21] | 50 | IA | 15 | Mucinous adenoma | None | N/A | TAH/BSO/PLN/OM + etoposide/CDDP | DOD 7 months |
Ding et al., 2014 [22] | 70 | IA | 16 | Borderline mucinous tumor | None | N/A | TAH/BSO/PLN/OM/AP | NED 6 months |
Sehouli et al., 2016 [23] | 23 | II | N/A | N/A | N/A | N/A | TAH/BSO/RPLN/OM/AP/colon resection + PTX/CBDCA | NED 111 months |
61 | I | N/A | N/A | N/A | N/A | TAH/BSO | NED 37 months | |
Doganay et al., 2019 [24] | 73 | II | 10 | Pure LCNEC | Uterus, bladder, rectum | Positive (malignant cells) | TAH/BSO/pelvic mass resection + etoposide/CDDP | AEW 6 months |